Characterization of Drug with Good Glass-Forming Ability Loaded Mesoporous Silica Nanoparticles and Its Impact Toward in vitro and in vivo Studies

References

• Budiman A, Nurfadilah N, Muchtaridi M, Sriwidodo S, Aulifa DL, Rusdin A. The Impact of Water-Soluble Chitosan on the Inhibition of Crystal Nucleation of Alpha-Mangostin from Supersaturated Solutions. Polymers. 2022;14(20):4370. doi:10.3390/polym14204370
   PubMed Web of Science ®Google Scholar
• Zhang G. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev. 2004;56(3):371–390. doi:10.1016/j.addr.2003.10.009
   PubMed Web of Science ®Google Scholar
• Budiman A, Aulifa DL. Characterization of drugs with good glass formers in loaded-mesoporous silica and its theoretical value relevance with mesopores surface and pore-filling capacity. Pharmaceuticals. 2022;15(1):93. doi:10.3390/ph15010093
   Web of Science ®Google Scholar
• Okada H, Ueda K, Yasuda Y, et al. Correlation between drug dissolution and resistance to water-induced phase separation in solid dispersion formulations revealed by solid-state NMR spectroscopy. Int J Pharm. 2020;577:119086. doi:10.1016/j.ijpharm.2020.119086
   PubMedGoogle Scholar
• Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci. 2010;99(9):3787–3806. doi:10.1002/jps.22197
   PubMed Web of Science ®Google Scholar
• Blaabjerg LI, Lindenberg E, Löbmann K, Grohganz H, Rades T. Is there a correlation between the glass forming ability of a drug and its supersaturation propensity? Int J Pharm. 2018;538(1–2):243–249. doi:10.1016/j.ijpharm.2018.01.013
   PubMedGoogle Scholar
• Blaabjerg LI, Lindenberg E, Löbmann K, Grohganz H, Rades T. Glass forming ability of amorphous drugs investigated by continuous cooling and isothermal transformation. Mol Pharm. 2016;13(9):3318–3325. doi:10.1021/acs.molpharmaceut.6b00650
   PubMed Web of Science ®Google Scholar
• Blaabjerg LI, Lindenberg E, Rades T, Grohganz H, Löbmann K. Influence of preparation pathway on the glass forming ability. Int J Pharm. 2017;521(1–2):232–238. doi:10.1016/j.ijpharm.2017.02.042
   PubMedGoogle Scholar
• Narayan R, Nayak U, Raichur A, Garg S. Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances. Pharmaceutics. 2018;10(3):118. doi:10.3390/pharmaceutics10030118
   PubMed Web of Science ®Google Scholar
• Slowing II, Trewyn BG, Lin VS-Y. Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. J Am Chem Soc. 2007;129(28):8845–8849. doi:10.1021/ja0719780
   PubMed Web of Science ®Google Scholar
• Deodhar GV, Adams ML, Trewyn BG. Controlled release and intracellular protein delivery from mesoporous silica nanoparticles. Biotechnol J. 2017;12(1). doi:10.1002/biot.201600408
   PubMed Web of Science ®Google Scholar
• Cha W, Fan R, Miao Y, et al. Mesoporous silica nanoparticles as carriers for intracellular delivery of nucleic acids and subsequent therapeutic applications. Molecules. 2017;22(5):782. doi:10.3390/molecules22050782
   PubMed Web of Science ®Google Scholar
• Tao C, Zhu Y, Xu Y, Zhu M, Morita H, Hanagata N. Mesoporous silica nanoparticles for enhancing the delivery efficiency of immunostimulatory DNA drugs. Dalton Trans. 2014;43(13):5142–5150. doi:10.1039/C3DT53433B
   PubMed Web of Science ®Google Scholar
• Möller K, Müller K, Engelke H, Bräuchle C, Wagner E, Bein T. Highly efficient siRNA delivery from core–shell mesoporous silica nanoparticles with multifunctional polymer caps. Nanoscale. 2016;8(7):4007–4019. doi:10.1039/C5NR06246B
   PubMed Web of Science ®Google Scholar
• Hanafi-Bojd MY, Ansari L, Malaekeh-Nikouei B. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles. Ther Deliv. 2016;7(9):649–655. doi:10.4155/tde-2016-0045
   PubMedGoogle Scholar
• Riikonen J, Xu W, Lehto VP. Mesoporous systems for poorly soluble drugs – recent trends. Int J Pharm. 2018;536(1):178–186. doi:10.1016/j.ijpharm.2017.11.054
   PubMed Web of Science ®Google Scholar
• Maleki A, Kettiger H, Schoubben A, Rosenholm JM, Ambrogi V, Hamidi M. Mesoporous silica materials: from physico-chemical properties to enhanced dissolution of poorly water-soluble drugs. J Control Release. 2017;262:329–347. doi:10.1016/j.jconrel.2017.07.047
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. 2015;11(2):313–327. doi:10.1016/j.nano.2014.09.014
   PubMed Web of Science ®Google Scholar
• Mamaeva V, Sahlgren C, Lindén M. Mesoporous silica nanoparticles in medicine—recent advances. Adv Drug Deliv Rev. 2013;65(5):689–702. doi:10.1016/j.addr.2012.07.018
   PubMed Web of Science ®Google Scholar
• Czarnobaj K, Prokopowicz M, Greber K. Use of materials based on polymeric silica as bone-targeted drug delivery systems for metronidazole. Int J Mol Sci. 2019;20(6):1311. doi:10.3390/ijms20061311
   PubMed Web of Science ®Google Scholar
• Šoltys M, Zůza D, Boleslavská T, et al. Drug loading to mesoporous silica carriers by solvent evaporation: a comparative study of amorphization capacity and release kinetics. Int J Pharm. 2021;607:120982. doi:10.1016/j.ijpharm.2021.120982
   PubMedGoogle Scholar
• Kinnari P, Mäkilä E, Heikkilä T, Salonen J, Hirvonen J, Santos HA. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int J Pharm. 2011;414(1–2):148–156. doi:10.1016/j.ijpharm.2011.05.021
   PubMed Web of Science ®Google Scholar
• Qian KK, Bogner RH. Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 1: thermodynamics of spontaneous amorphization. J Pharm Sci. 2011;100(7):2801–2815. doi:10.1002/jps.22519
   PubMed Web of Science ®Google Scholar
• Andersson J, Rosenholm J, Areva S, Lindén M. Influences of material characteristics on ibuprofen drug loading and release profiles from ordered micro- and mesoporous silica matrices. Chem Mater. 2004;16(21):4160–4167. doi:10.1021/cm0401490
   Web of Science ®Google Scholar
• Genina N, Hadi B, Löbmann K. Hot melt extrusion as solvent-free technique for a continuous manufacturing of drug-loaded mesoporous silica. J Pharm Sci. 2018;107(1):149–155. doi:10.1016/j.xphs.2017.05.039
   PubMed Web of Science ®Google Scholar
• Hempel NJ, Brede K, Olesen NE, Genina N, Knopp MM, Löbmann K. A fast and reliable DSC-based method to determine the monomolecular loading capacity of drugs with good glass-forming ability in mesoporous silica. Int J Pharm. 2018;544(1):153–157. doi:10.1016/j.ijpharm.2018.04.035
   PubMedGoogle Scholar
• Bavnhøj CG, Knopp MM, Madsen CM, Löbmann K. The role interplay between mesoporous silica pore volume and surface area and their effect on drug loading capacity. Int J Pharm X. 2019;1:100008. doi:10.1016/j.ijpx.2019.100008
   PubMedGoogle Scholar
• Kawakami K. Crystallization tendency of pharmaceutical glasses: relevance to compound properties, impact of formulation process, and implications for design of amorphous solid dispersions. Pharmaceutics. 2019;11(5):202. doi:10.3390/pharmaceutics11050202
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Dalwadi SJ, Thakkar VT, Soni TG, Gohel MC, Gandhi TR. Improvement of dissolution rate of aceclofenac by solid dispersion technique. Powder Technol. 2011;207(1–3):47–54. doi:10.1016/j.powtec.2010.10.009
   Web of Science ®Google Scholar
• Iolascon G, Giménez S, Mogyorósi D. A review of aceclofenac: analgesic and anti-inflammatory effects on musculoskeletal disorders. J Pain Res. 2021;14:3651–3663. doi:10.2147/JPR.S326101
   PubMed Web of Science ®Google Scholar
• Balata G, Bakera R, Mahdi M. Improvement of solubility and dissolution properties of clotrimazole by solid dispersions and inclusion complexes. Indian J Pharm Sci. 2011;73(5):517. doi:10.4103/0250-474X.98995
   PubMed Web of Science ®Google Scholar
• Crowley PD, Gallagher HC. Clotrimazole as A pharmaceutical: past, present and future. J Appl Microbiol. 2014;117(3):611–617. doi:10.1111/jam.12554
   PubMed Web of Science ®Google Scholar
• Amr S. Formulation, characterization and In-Vitro release of oral felodipine self-nanoemulsifying drug delivery Systems. Al-Azhar J Pharm Sci. 2018;57(1):18–51. doi:10.21608/ajps.2018.46619
   Google Scholar
• Fuhr LM, Marok FZ, Mees M, Mahfoud F, Selzer D, Lehr T. A physiologically based pharmacokinetic and pharmacodynamic model of the CYP3A4 substrate felodipine for drug–drug interaction modeling. Pharmaceutics. 2022;14(7):1474. doi:10.3390/pharmaceutics14071474
   PubMed Web of Science ®Google Scholar
• Vimalson DC, Parimalakrishnan S, Jeganathan NS, Anbazhagan S. Enhancement of Solubility and dissolution characteristics of fenofibrate by solid dispersion technique. Int Research J Pharm. 2018;9(10):145–150. doi:10.7897/2230-8407.0910242
   Google Scholar
• Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088–2093.
   PubMed Web of Science ®Google Scholar
• Friuli V, Bruni G, Musitelli G, Conte U, Maggi L. Influence of dissolution media and presence of alcohol on the in vitro performance of pharmaceutical products containing an insoluble drug. J Pharm Sci. 2018;107(1):507–511. doi:10.1016/j.xphs.2017.06.001
   PubMed Web of Science ®Google Scholar
• González-Barnadas A, Camps-Font O, Martín-Fatás P, Figueiredo R, Gay-Escoda C, Valmaseda-Castellón E. Efficacy and safety of selective COX-2 inhibitors for pain management after third molar removal: a meta-analysis of randomized clinical trials. Clin. Oral Investig. 2020;24(1):79–96.
   PubMed Web of Science ®Google Scholar
• Bahl D, Bogner RH. Amorphization alone does not account for the enhancement of solubility of drug co-ground with silicate: the case of indomethacin. AAPS Pharm Sci Tech. 2008;9(1):146–153. doi:10.1208/s12249-007-9013-9
   PubMed Web of Science ®Google Scholar
• Lucas S. The Pharmacology of Indomethacin. Headache. 2016;56(2):436–446.
   PubMed Web of Science ®Google Scholar
• Kozyra A, Mugheirbi NA, Paluch KJ, Garbacz G, Tajber L. Phase diagrams of polymer-dispersed liquid crystal systems of itraconazole/component immiscibility induced by molecular anisotropy. Mol Pharm. 2018;15(11):5192–5206. doi:10.1021/acs.molpharmaceut.8b00724
   PubMedGoogle Scholar
• De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:27–37.
   PubMed Web of Science ®Google Scholar
• Pashazadeh‐Panahi P, Hasanzadeh M, Eivazzadeh‐Keihan R. Spectrophotometric study of ketoconazole binding with citrate capped silver nanoparticles and its monitoring in human plasma samples. J Mol Recognit. 2020;33(5). doi:10.1002/jmr.2830
   Web of Science ®Google Scholar
• Van Tyle JH; Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984;4(6):343–373.
   PubMed Web of Science ®Google Scholar
• Gantiva M, Martínez F. Thermodynamic analysis of the solubility of ketoprofen in some propylene glycol+ water cosolvent mixtures. Fluid Phase Equilib. 2010;293(2):242–250.
   Web of Science ®Google Scholar
• Carbone C, Rende P, Comberiati P, Carnovale D, Mammí M, De Sarro G. The safety of ketoprofen in different ages. J Pharmacol Pharmacother. 2013;4(1_suppl):S99–S103. doi:10.4103/0976-500X.120967
   PubMedGoogle Scholar
• Kundawala AJ, Patel PH. Solubility enhancement of loratadine by solid dispersion techniques. Int J Chemtech Res. 2017;10(7):207–217.
   Google Scholar
• Baroody FM, Naclerio RM. Antiallergic effects of H1-receptor antagonists. Allergy. 2000;55(Suppl 64):17–27.
   PubMedGoogle Scholar
• Shahzadi I, Masood MI, Chowdhary F, et al. Microemulsion Formulation for Topical Delivery of Miconazole Nitrate. Int J Pharm Sci Rev Res. 2014;24(2):30–36.
   Google Scholar
• Mazzarino M, Comunità F, de la Torre X, Molaioni F, Botrè F. Effects of the administration of miconazole by different routes on the biomarkers of the “steroidal module” of the athlete biological passport. Drug Test Anal. 2021;13(10):1712–1726. doi:10.1002/dta.3121
   PubMed Web of Science ®Google Scholar
• Surov AO, Voronin AP, Drozd KV, et al. Polymorphic forms of antiandrogenic drug nilutamide: structural and thermodynamic aspects. Phys Chem Chem Phys. 2021;23(16):9695–9708. doi:10.1039/D1CP00793A
   PubMed Web of Science ®Google Scholar
• Rashid M, Shamshavali K, Chhabra M. Efficacy and safety of nilutamide in patients with metastatic prostate cancer who underwent orchiectomy: a systematic review and metaanalysis. Curr Clin Pharmacol. 2019;14(2):108–115. doi:10.2174/1574884714666190112151202
   PubMed Web of Science ®Google Scholar
• Piel G, Pirotte B, Delneuville I, et al. Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide–L-lysine–cyclodextrin complexes. J Pharm Sci. 1997;86(4):475–480.
   PubMed Web of Science ®Google Scholar
• Vunnam N, Young MC, Liao EE, et al. Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †. Cancer Biol Ther. 2023;24(1). doi:10.1080/15384047.2023.2176692
   PubMed Web of Science ®Google Scholar
• Kamisetti RR, Mekala M, Muvvala S, Penmatsa DB. Fast dissolving tablets of pimozide: design, optimization and in vitro characterization. Indones J Pharm. 2015;26(2):114. doi:10.14499/indonesianjpharm26iss2pp114
   Google Scholar
• Ranjan A, Kaushik I, Srivastava SK. Pimozide suppresses the growth of brain tumors by targeting stat3-mediated autophagy. Cells. 2020;9(9):2141. doi:10.3390/cells9092141
   PubMed Web of Science ®Google Scholar
• Han L, Yang Q, Shen T, Qing J, Wang J. Lymphatic transport of orally administered probucol-loaded mPEG-DSPE micelles. Drug Deliv. 2015;1–7. doi:10.3109/10717544.2015.1028600
   Web of Science ®Google Scholar
• Liu HW, Luo Y, Zhou YF, Chen ZP. Probucol prevents diabetes-induced retinal neuronal degeneration through upregulating Nrf2. Biomed Res Int. 2020;2020:1–8. doi:10.1155/2020/3862509
   Web of Science ®Google Scholar
• Loftsson T. Degradation Pathways. In: Drug Stability for Pharmaceutical Scientists. Vol. 3. 1st ed. Academic Press; 2014:63–104.
   Google Scholar
• Ford DJ, Raj PP, Singh P, Regan KM, Ohlweiler D. Differential peripheral nerve block by local anesthetics in the cat. Anesthesiology. 1984;60(1):28–33.
   PubMed Web of Science ®Google Scholar
• Morris JB, Tisi DA, Tan DCT, Worthington JH. Development and Palatability assessment of norvir® (Ritonavir) 100 mg powder for pediatric population. Int J Mol Sci. 2019;20(7):1718. doi:10.3390/ijms20071718
   PubMed Web of Science ®Google Scholar
• Loelius SG, Lannan KL, Blumberg N, Phipps RP, Spinelli SL. The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro. Thromb Res. 2018;169:96–104.
   PubMed Web of Science ®Google Scholar
• Corma A. From microporous to mesoporous molecular sieve materials and their use in catalysis. Chem Rev. 1997;97(6):2373–2420. doi:10.1021/cr960406n
   PubMed Web of Science ®Google Scholar
• Knežević NŽ, Durand JO. Large pore mesoporous silica nanomaterials for application in delivery of biomolecules. Nanoscale. 2015;7(6):2199–2209. doi:10.1039/C4NR06114D
   PubMed Web of Science ®Google Scholar
• Jana SK, Nishida R, Shindo K, Kugita T, Namba S. Pore size control of mesoporous molecular sieves using different organic auxiliary chemicals. Microporous Mesoporous Mater. 2004;68(1–3):133–142. doi:10.1016/j.micromeso.2003.12.010
   Web of Science ®Google Scholar
• Widenmeyer M, Anwander R. Pore size control of highly ordered mesoporous silica MCM-48. Chem Mater. 2002;14(4):1827–1831. doi:10.1021/cm011273b
   Web of Science ®Google Scholar
• Zhang L, Qiao S, Jin Y, et al. Fabrication and size‐selective bioseparation of magnetic silica nanospheres with highly ordered periodic mesostructure. Adv Funct Mater. 2008;18(20):3203–3212. doi:10.1002/adfm.200800363
   Web of Science ®Google Scholar
• Kruk M. Access to ultralarge-pore ordered mesoporous materials through selection of surfactant/swelling-agent micellar templates. Acc Chem Res. 2012;45(10):1678–1687. doi:10.1021/ar200343s
   PubMed Web of Science ®Google Scholar
• Lettow JS, Han YJ, Schmidt-Winkel P, et al. Hexagonal to mesocellular foam phase transition in polymer-templated mesoporous silicas. Langmuir. 2000;16(22):8291–8295. doi:10.1021/la000660h
   Web of Science ®Google Scholar
• Feng P, Bu X, Stucky GD, Pine DJ. Monolithic mesoporous silica templated by microemulsion liquid crystals. J Am Chem Soc. 2000;122(5):994–995. doi:10.1021/ja992921j
   Web of Science ®Google Scholar
• Ulagappan N, Rao CNR. Evidence for supramolecular organization of alkane and surfactant molecules in the process of forming mesoporous Silica. Chem Comm. 1996;(24):2759. doi:10.1039/cc9960002759
   Web of Science ®Google Scholar
• Mandal M, Kruk M. Versatile approach to synthesis of 2-D hexagonal ultra-large-pore periodic mesoporous organosilicas. J Mater Chem. 2010;20(35):7506. doi:10.1039/c0jm01170c
   Web of Science ®Google Scholar
• Sayari A, Yang Y, Kruk M, Jaroniec M. Expanding the pore size of MCM-41 silicas: use of amines as expanders in direct synthesis and postsynthesis procedures. J Phys Chem B. 1999;103(18):3651–3658. doi:10.1021/jp984504j
   Web of Science ®Google Scholar
• Zhang J, Rosenholm JM, Gu H. Molecular confinement in fluorescent magnetic mesoporous silica nanoparticles: effect of pore size on multifunctionality. Chem Phys Chem. 2012;13(8):2016–2019. doi:10.1002/cphc.201100943
   Google Scholar
• Zhang J, Li X, Rosenholm JM, chen GH. Synthesis and characterization of pore size-tunable magnetic mesoporous silica nanoparticles. J Colloid Interface Sci. 2011;361(1):16–24. doi:10.1016/j.jcis.2011.05.038
   PubMed Web of Science ®Google Scholar
• Wu SH, Mou CY, Lin HP. Synthesis of mesoporous silica nanoparticles. Chem Soc Rev. 2013;42(9):3862. doi:10.1039/c3cs35405a
   PubMed Web of Science ®Google Scholar
• Chiang YD, Lian HY, Leo SY, Wang SG, Yamauchi Y, Wu KCW. Controlling particle size and structural properties of mesoporous silica nanoparticles using the Taguchi method. J Phys Chem C. 2011;115(27):13158–13165. doi:10.1021/jp201017e
   Web of Science ®Google Scholar
• Qiao ZA, Zhang L, Guo M, Liu Y, Huo Q. Synthesis of mesoporous silica nanoparticles via controlled hydrolysis and condensation of silicon alkoxide. Chem Mater. 2009;21(16):3823–3829. doi:10.1021/cm901335k
   Web of Science ®Google Scholar
• Fowler CE, Khushalani D, Lebeau B, Mann S. Nanoscale materials with mesostructured interiors. Adv Mater. 2001;13(9):649–652. doi:10.1002/1521-4095(200105)13:9
   Web of Science ®Google Scholar
• Ma K, Sai H, Wiesner U. Ultrasmall Sub-10 nm near-infrared fluorescent mesoporous silica nanoparticles. J Am Chem Soc. 2012;134(32):13180–13183. doi:10.1021/ja3049783
   PubMed Web of Science ®Google Scholar
• Lv X, Zhang L, Xing F, Lin H. Controlled synthesis of monodispersed mesoporous silica nanoparticles: particle size tuning and formation mechanism investigation. Microporous Mesoporous Mater. 2016;225:238–244. doi:10.1016/j.micromeso.2015.12.024
   Web of Science ®Google Scholar
• Manzano M, Vallet‐Regí M. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020;30(2). doi:10.1002/adfm.201902634
   Web of Science ®Google Scholar
• Rosenholm M, Sahlgren J, Linden C. Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment. Curr Drug Targets. 2011;12(8):1166–1186. doi:10.2174/138945011795906624
   PubMed Web of Science ®Google Scholar
• Fuyuhiko T. Mesoporous Silica-Based Nanomaterials and Biomedical Applications - Part A. 1st ed. Academic Press; 2018.
   Google Scholar
• Ambrogio MW, Thomas CR, Zhao YL, Zink JI, Stoddart JF. Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res. 2011;44(10):903–913. doi:10.1021/ar200018x
   PubMed Web of Science ®Google Scholar
• Lee JE, Lee N, Kim T, Kim J, Hyeon T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc Chem Res. 2011;44(10):893–902. doi:10.1021/ar2000259
   PubMed Web of Science ®Google Scholar
• Peng F, Su Y, Zhong Y, Fan C, Lee ST, He Y. Silicon nanomaterials platform for bioimaging, biosensing, and cancer therapy. Acc Chem Res. 2014;47(2):612–623. doi:10.1021/ar400221g
   PubMed Web of Science ®Google Scholar
• Patil LD, Verma U, Patil UD, Naik JB, Narkhede JS. Inclusion of aceclofenac in mesoporous silica nanoparticles: drug release study and statistical optimization of encapsulation efficiency by response surface methodology. Mater Technol. 2019;34(12):751–763. doi:10.1080/10667857.2019.1624301
   Web of Science ®Google Scholar
• Kumar D, Sailaja Chirravuri SV, Shastri NR. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac. Int J Pharm. 2014;461(1–2):459–468. doi:10.1016/j.ijpharm.2013.12.017
   PubMed Web of Science ®Google Scholar
• Gignone A, Manna L, Ronchetti S, Banchero M, Onida B. Incorporation of clotrimazole in ordered mesoporous silica by supercritical CO2. Microporous Mesoporous Mater. 2014;200:291–296. doi:10.1016/j.micromeso.2014.05.031
   Web of Science ®Google Scholar
• Le TT, Elzhry Elyafi AK, Mohammed AR, Al-Khattawi A. Delivery of Poorly Soluble Drugs via Mesoporous Silica: impact of Drug Overloading on Release and Thermal Profiles. Pharmaceutics. 2019;11(6):269. doi:10.3390/pharmaceutics11060269
   PubMed Web of Science ®Google Scholar
• Wu C, Zhao Z, Zhao Y, Hao Y, Liu Y, Liu C. Preparation of a push–pull osmotic pump of felodipine solubilized by mesoporous silica nanoparticles with a core–shell structure. Int J Pharm. 2014;475(1–2):298–305. doi:10.1016/j.ijpharm.2014.08.033
   PubMedGoogle Scholar
• Hu L, Sun H, Zhao Q, et al. Multilayer encapsulated mesoporous silica nanospheres as an oral sustained drug delivery system for the poorly water-soluble drug felodipine. Mater Sci Eng C. 2015;47:313–324. doi:10.1016/j.msec.2014.10.067
   PubMed Web of Science ®Google Scholar
• Ahern RJ, Hanrahan JP, Tobin JM, Ryan KB, Crean AM. Comparison of fenofibrate–mesoporous silica drug-loading processes for enhanced drug delivery. Eur J Pharm Sci. 2013;50(3–4):400–409. doi:10.1016/j.ejps.2013.08.026
   PubMed Web of Science ®Google Scholar
• Van Speybroeck M, Mellaerts R, Mols R, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. 2010;41(5):623–630. doi:10.1016/j.ejps.2010.09.002
   PubMed Web of Science ®Google Scholar
• Uejo F, Limwikrant W, Moribe K, Yamamoto K. Dissolution improvement of fenofibrate by melting inclusion in mesoporous silica. Asian J Pharm Sci. 2013;8(6):329–335. doi:10.1016/j.ajps.2013.11.001
   Google Scholar
• Wu C, Zhao Z, Zhao Y, Hao Y, Liu Y, Zhao W. Development of an oral push-pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles. Int J Nanomed. 2015;1691. doi:10.2147/IJN.S76755
   PubMed Web of Science ®Google Scholar
• Charnay C, Bégu S, Tourné-Péteilh C, Nicole L, Lerner DA, Devoisselle JM. Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. Eur J Pharm Biopharm. 2004;57(3):533–540. doi:10.1016/j.ejpb.2003.12.007
   PubMed Web of Science ®Google Scholar
• Wang Y, Ke J, Gou K, et al. Amino functionalized mesoporous silica with twisted rod-like shapes: synthetic design, in vitro and in vivo evaluation for ibuprofen delivery. Microporous Mesoporous Mater. 2020;294:109896. doi:10.1016/j.micromeso.2019.109896
   Web of Science ®Google Scholar
• Braz WR, Rocha NL, de Faria EH, et al. Incorporation of anti-inflammatory agent into mesoporous silica. Nanotechnology. 2016;27(38):385103. doi:10.1088/0957-4484/27/38/385103
   PubMed Web of Science ®Google Scholar
• Zhang W, Zheng N, Chen L, et al. Effect of shape on mesoporous silica nanoparticles for oral delivery of indomethacin. Pharmaceutics. 2018;11(1):4. doi:10.3390/pharmaceutics11010004
   PubMed Web of Science ®Google Scholar
• Ferreira NH, Ribeiro AB, Rinaldi-Neto F, et al. Anti-melanoma activity of indomethacin incorporated into mesoporous silica nanoparticles. Pharm Res. 2020;37(9):172. doi:10.1007/s11095-020-02903-y
   PubMed Web of Science ®Google Scholar
• Ren X, Cheng S, Liang Y, et al. Mesoporous silica nanospheres as nanocarriers for poorly soluble drug itraconazole with high loading capacity and enhanced bioavailability. Microporous Mesoporous Mater. 2020;305:110389. doi:10.1016/j.micromeso.2020.110389
   Web of Science ®Google Scholar
• Masood A, Maheen S, Khan HU, et al. Pharmaco-technical evaluation of statistically formulated and optimized dual drug-loaded silica nanoparticles for improved antifungal efficacy and wound healing. ACS Omega. 2021;6(12):8210–8225. doi:10.1021/acsomega.0c06242
   PubMed Web of Science ®Google Scholar
• Abd-Elrahman AA, El Nabarawi MA, Hassan DH, Taha AA. Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro / in vivo characterization. Drug Deliv. 2016;23(9):3387–3398. doi:10.1080/10717544.2016.1186251
   PubMed Web of Science ®Google Scholar
• Guo Y, Wu L, Gou K, et al. Functional mesoporous silica nanoparticles for delivering nimesulide with chiral recognition performance. Microporous Mesoporous Mater. 2020;294:109862. doi:10.1016/j.micromeso.2019.109862
   Web of Science ®Google Scholar
• Lau M, Giri K, Garcia-Bennett AE. Antioxidant Properties of Probucol Released from Mesoporous Silica. Eur J Pharm Sci. 2019;138:105038. doi:10.1016/j.ejps.2019.105038
   PubMed Web of Science ®Google Scholar
• Ayad MM, Salahuddin NA, Torad NL, El-Nasr AA. pH-responsive sulphonated mesoporous silica: a comparative drug release study. RSC Adv. 2016;6(63):57929–57940. doi:10.1039/C6RA07022A
   Web of Science ®Google Scholar
• Dening TJ, Taylor LS. Supersaturation potential of ordered mesoporous silica delivery systems. part 1: dissolution performance and drug membrane transport rates. Mol Pharm. 2018;15(8):3489–3501. doi:10.1021/acs.molpharmaceut.8b00488
   PubMedGoogle Scholar
• Mahajan M, Rajput S. Development of mesoporous silica nanoparticles of ritonavir with enhanced bioavailability potential: formulation optimization, in-vitro and in-vivo evaluation. Int J Pharm Sci Res. 2018;9(10):4127–4137.
   Google Scholar
• Trzeciak K, Chotera-Ouda A, Bak-Sypien II, Potrzebowski MJ. Mesoporous silica particles as drug delivery systems—the state of the art in loading methods and the recent progress in analytical techniques for monitoring these processes. Pharmaceutics. 2021;13(7):950. doi:10.3390/pharmaceutics13070950
   PubMed Web of Science ®Google Scholar
• Budiman A, Aulifa DL. A comparative study of the pharmaceutical properties between amorphous drugs loaded-mesoporous silica and pure amorphous drugs prepared by solvent evaporation. Pharmaceuticals. 2022;15(6):730. doi:10.3390/ph15060730
   Web of Science ®Google Scholar
• Dengale SJ, Ranjan OP, Hussen SS, et al. Preparation and characterization of co-amorphous ritonavir–indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions. Eur J Pharm Sci. 2014;62:57–64. doi:10.1016/j.ejps.2014.05.015
   PubMed Web of Science ®Google Scholar
• Acharya M, Mishra S, Sahoo N, Mallick R. Infrared spectroscopy for analysis of co-processed ibuprofen and magnesium trisilicate at milling and freeze drying. Acta Chim Slov. 2017;45–54. doi:10.17344/acsi.2016.2772
   PubMed Web of Science ®Google Scholar
• Budiman A, Aulifa DL. Encapsulation of drug into mesoporous silica by solvent evaporation: a comparative study of drug characterization in mesoporous silica with various molecular weights. Heliyon. 2021;7(12):e08627. doi:10.1016/j.heliyon.2021.e08627
   PubMed Web of Science ®Google Scholar
• Pretsch E, Bühlmann P, Affolter C. Structure Determination of Organic Compounds. Tables of Spectral Data. 3rd ed. Springer; 2000.
   Google Scholar
• Tang Q, Xu Y, Wu D, Sun Y. A study of carboxylic-modified mesoporous silica in controlled delivery for drug famotidine. J Solid State Chem. 2006;179(5):1513–1520. doi:10.1016/j.jssc.2006.02.004
   Web of Science ®Google Scholar
• Moritz M, Łaniecki M. SBA-15 mesoporous material modified with APTES as the carrier for 2-(3-Benzoylphenyl)propionic acid. Appl Surf Sci. 2012;258(19):7523–7529. doi:10.1016/j.apsusc.2012.04.076
   Web of Science ®Google Scholar
• McCarthy CA, Ahern RJ, Devine KJ, Crean AM. Role of Drug Adsorption onto the Silica Surface in Drug Release from Mesoporous Silica Systems. Mol Pharm. 2018;15(1):141–149. doi:10.1021/acs.molpharmaceut.7b00778
   PubMedGoogle Scholar
• Kjellman T, Xia X, Alfredsson V, Garcia-Bennett AE. Influence of microporosity in SBA-15 on the release properties of anticancer drug dasatinib. J Mater Chem B. 2014;2(32):5265. doi:10.1039/C4TB00418C
   PubMed Web of Science ®Google Scholar
• Ilevbare GA, Taylor LS. Liquid–liquid phase separation in highly supersaturated aqueous solutions of poorly water-soluble drugs: implications for solubility enhancing formulations. Cryst Growth Des. 2013;13(4):1497–1509. doi:10.1021/cg301679h
   Web of Science ®Google Scholar
• Dening TJ, Zemlyanov D, Taylor LS. Application of an adsorption isotherm to explain incomplete drug release from ordered mesoporous silica materials under supersaturating conditions. J Control Release. 2019;307:186–199. doi:10.1016/j.jconrel.2019.06.028
   PubMed Web of Science ®Google Scholar
• Li W, Quan P, Zhang Y, et al. Influence of drug physicochemical properties on absorption of water insoluble drug nanosuspensions. Int J Pharm. 2014;460(1–2):13–23. doi:10.1016/j.ijpharm.2013.10.038
   PubMed Web of Science ®Google Scholar
• Buckley ST, Frank KJ, Fricker G, Brandl M. Biopharmaceutical classification of poorly soluble drugs with respect to “enabling formulations. Eur J Pharm Sci. 2013;50(1):8–16. doi:10.1016/j.ejps.2013.04.002
   PubMed Web of Science ®Google Scholar
• Fong SYK, Martins SM, Brandl M, Bauer-Brandl A. Solid phospholipid dispersions for oral delivery of poorly soluble drugs: investigation into celecoxib incorporation and solubility-in vitro permeability enhancement. J Pharm Sci. 2016;105(3):1113–1123. doi:10.1016/S0022-3549(15)00186-0
   PubMed Web of Science ®Google Scholar
• Jacobsen AC, Elvang PA, Bauer-Brandl A, Brandl M. A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib. Eur J Pharm Sci. 2019;127:199–207. doi:10.1016/j.ejps.2018.11.003
   PubMed Web of Science ®Google Scholar
• Ueda K, Higashi K, Kataoka M, Yamashita S, Yamamoto K, Moribe K. Inhibition mechanism of hydroxypropyl methylcellulose acetate succinate on drug crystallization in gastrointestinal fluid and drug permeability from A supersaturated Solution. Eur J Pharm Sci. 2014;62:293–300. doi:10.1016/j.ejps.2014.06.007
   PubMed Web of Science ®Google Scholar